Biotricity launches Biocare Telemed for safe and convenient remote patient care

Secure HIPAA compliant technology for at-risk chronic care patients

NOVEMBER 12, 2020 | BY BIOTRICITY

REDWOOD CITY, Calif., Nov 12, 2020 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today introduced Biocare Telemed, a virtual clinic that provides user-friendly access for patients to receive outstanding medical care and remote patient cardiac monitoring from their physician of choice in the safety and comfort of their home.

“The arrival of COVID-19 has highlighted the importance of having remote care systems in place,” said Dr. Waqaas Al-Siddiq, founder & CEO, Biotricity Inc. “Biocare Telemed streamlines the process, allowing patients to skip the waiting room and receive excellent medical care when and where it’s needed without leaving the house.”

The Biocare Telemed platform is a complete solution for the clinic with the ability to book and manage appointments, connect diagnostic tools, and report, monitor and diagnose remotely using the Bioflux.

Traditional telemedicine provides consults for routine clinical needs as opposed to supporting the diagnostic and more complex needs of cardiac patients. With Biocare Telemed, clinicians can provide outstanding medical care to at-risk patients and those needing remote cardiac monitoring without leaving the safety of their home. The user-friendly platform helps ensure seamless integration into the clinics’ current workflow, saving time and reducing costs.

“Being able to provide my at-risk cardiac patients a HIPAA compliant telemedicine solution for virtual consults during COVID-19 has changed how I practice medicine,” said Dr. John Lassetter, president, Radial Heart First Clinic. “Biocare Telemed allows me to monitor and diagnose my patients from the safety of their homes. Telemedicine is here to stay as more and more patients are demanding virtual consults, and clinicians realize the benefits of it to their practices.”

Biotricity will initially offer the Biocare Telemed platform via limited release to selected physicians, followed by a broad rollout in Q4 2020.

For more information, visit www.biotricity.com.

About Biotricity Inc.

Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity’s unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit www.biotricity.com.

MEDIA CONTACT:

Donna Loughlin Michaels
LMGPR
408.393.5575
donna@lmgpr.com

Important Cautions Regarding Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” “project,” or “goal” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company’s future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company’s inability to expand the Company’s business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC. There cannot be any assurance that the Company will ever become profitable. During the three months ended June 30, 2020 the Company incurred a net loss attributable to common stockholders of $3.4 million. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

Contacts:

Investor relations:

Biotricity Investor Relations
Investors@biotricity.com
1.800.951.3348